Skip to Content

Amifampridine use while Breastfeeding

Drugs containing Amifampridine: Firdapse, Ruzurgi

Medically reviewed by Drugs.com. Last updated on Aug 20, 2020.

Amifampridine Levels and Effects while Breastfeeding

Summary of Use during Lactation

No information is available on the clinical use of amifampridine during breastfeeding on the presence of amifampridine or the 3-N-acetyl-amifampridine metabolite in breastmilk. If amifampridine is required by the mother, it is not a reason to discontinue breastfeeding, but the infant should be carefully monitored for excessive crying or fussiness, adequate weight gain, and developmental milestones.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Amifampridine

CAS Registry Number

54-96-6

Drug Class

  • Breastfeeding
  • Lactation
  • Neuromuscular Agents
  • Potassium Channel Blockers

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.